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Abstract: Burn wounds are highly debilitating injuries, with significant morbidity and mortality rates
worldwide. In association with the damage of the skin integrity, the risk of infection is increased,
posing an obstacle to healing and potentially leading to sepsis. Another limitation against healing is
associated with antibiotic resistance mainly due to the use of systemic antibiotics for the treatment
of localized infections. Nanotechnology has been successful in finding strategies to incorporate
antibiotics in nanoparticles for the treatment of local wounds, thereby avoiding the systemic exposure
to the drug. This review focuses on the most recent advances on the use of nanoparticles in wound
dressing formulations and in tissue engineering for the treatment of burn wound infections.
Keywords: burn wound infection; antibiotics; wound healing; nanoparticles
1. Introduction
Burn injuries are one of the most frequent causes of trauma, leading to morbidity and mortality
mostly in low and middle-income countries. Burns can be caused by the (i) contact to high temperature
materials (e.g., contact with fire or hot liquids, solids or gases), or by the (ii) exposure to cold
environments, chemical agents (e.g., strong acids or bases), electricity or radiation exposure (e.g.,
ultra-violet light, X-ray, microwaves and others) [1]. Scald injuries are the most common type of burns
in children, adults, and elderly patients [2].
Burns affect the integrity of the skin as its protective function is significantly compromised,
allowing microbial invasion to occur, increasing the risk of localized colonization and systemic entry of
microbes from both endogenous and exogenous origins [3]. According to the World Health Organization
(WHO), burn injuries comprise over an estimated 180,000 annual deaths, representing a global public
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health problem [4]. In the Western world, the mortality rate due to burns has been declining, for
example in England and Wales the rate is approximately 1.4% of all cases [2]. Per year, in Europe,
the hospitalization rate is 2–29 hospitalizations per 100,000 inhabitants, and these injuries have a
high impact, at the economic level, because they lead to long hospitalization periods and entail many
costs. In Portugal, the latest surveys showed that the hospitalization rate was 18.9 hospitalizations/
100,000 inhabitants/year between 2000–2013. This study is one of the largest southern European
nationwide epidemiological study of burn patients and allowed to conclude that burn admissions are
decreasing significantly [5].
Some groups, such as patients with diabetic neuropathy, patients with mental disorders,
and children, are more vulnerable to these injuries [2]. In the case of children, there is a special
care to be taken, because burns are the 11th cause of death in children between 1–9 years old and are
the 5th cause of non-fatal injuries. Burns have a high impact on patients, both at physical level (due to
disfigurement or disability), and at emotional level [6].
The survival rate has been increasing mainly because of improvements in various therapies
such as pulmonary care, nutritional support, burn wound care and others. However, even though burn
wounds are initially sterile in comparison to other acute skin injuries, in patients with more than 40%
of the total body surface area (TBSA) burned, 75% of deaths are due to sepsis [7]. Thus, it is important
to ascertain what bacteria are present in burn wounds and their resistance [8].
Burn wounds differ from any of the other traumatic wounds, being the immunosuppression the
major cause of sepsis from invasive burn wound. Due to the increased capillary permeability, a high loss
of plasma is observed in extensive burn wounds, which may lead to shock. Chemotactic, phagocytic
and intracellular killing events are observed, together with the depression of cytokinin release and
cell-mediated immune response, thereby reducing immunoglobulin serum levels, and compromising
B-cell differentiation into antibody secreting cells. The highest incidence of septicaemia in burns
occurs within the first 10 days, when serum immunoglobulin titres are markedly deranged [7].
The microorganisms that may cause invasive burn wound infection are summarized in Table 1.
Table 1. Microorganisms that cause invasive burn wound infections.
Group Species
Gram-positive organisms
Staphylococcus aureus
Methicillin-resistant Staphylococcus aureus (MRSA)
Coagulase-negative staphylococci
Enterococcus spp.
Vancomycin-resistant enterococci
Gram-negative organisms
Pseudomonas aeruginosa
Escherichia coli
Klebsiellapneumoniae
Enterobacter spp.
Proteus spp.
Acinetobacter spp.
Bacteroides spp.
Fungi Candida spp.
Aspergillus spp.
Viruses
Herpes simplex
Cytomegalovirus
Varicella-zoster virus
In order to prevent the incidence of infection and sepsis, new therapeutic approaches are required,
and nanomedicine is an area that can be extensively explored [9]. As the application of nanotechnology
in medical care, nanomedicine is a promising area as it combines an improvement in health care with
a reduction of the costs of therapy. In Europe, only a few nanomedicines have yet been approved
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when compared to the USA [10]. The approval of nanomedicines has encountered several obstacles
attributed to the difficulty of fully describing the mechanism of action and interaction of nanomedicines
with the biological systems, and also of scaling-up of manufacturing and quality control methods that
are important for batch to batch uniformity [11–13]. The European Medicines Agency (EMA) may
be open to new authorizations because clinical trials with nanomedicines have being increasing in
Europe in the last decades. Studies on follow up, use, compliance, and assessment in this area are
nevertheless still needed [14–17]. Regenerative medicine is one of the branches of nanomedicine that is
most promising for the approval of new medicines and therapies [10].
Nanomedicine has the potential to improve treatments for non-curable diseases or diseases with
poor prognosis, such as cancer, neurodegenerative diseases or infections. Nanosystems have been
firstly proposed as carriers for drug delivery and targeting, but today nanomaterials themselves
can also exhibit therapeutic properties [18]. As the most newly developed pharmaceuticals and
nanonutraceuticals are poorly soluble drugs [19–33], the emerging field of nanotechnology presents
as a very promising therapeutic alternative for topical wound healing treatment with its underlying
target delivery mechanisms [9,34]. This review discusses the latest advances in nanomedicines and
their relevance and advantages for the treatment of burn wound infections.
2. Pathophysiology of Burn Wound Infections
An injured skin derived from a burn wound can be classified according to the depth of the thermal
damage (classified into four degrees) and the estimation of percentage of total body surface area (TBSA)
that has been affected (determined by the rule of nines) [1]. The susceptibility to infection is highly
influenced by the severity of the damage and may cause, in some more advanced cases, severe lesions
to the underlying tissues of the skin. The depth of thermal skin damage is represented in Figure 1.
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cutaneous appendages and connective tissue [35], providing structural support, glandular function 
and irrigation [1]. Adipocytes, macrophages, fibroblasts, vascular, and nerve systems form the 
hypodermis and support the above-mentioned layers of tissue. 
When skin integrity is compromised by wound injury, a restorative response for cutaneous 
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aims to prevent the microorganism invasion. Simultaneously, the inflammation is installed, as the
fibrin clot secrets cytokines and growth factors that induce the migration of neutrophils followed by
macrophages (differentiated lymphocytes and monocytes) to the wound resulting in the production of
reactive oxygen species (ROS) and proteinases, thereby protecting the organism against exogenous
microorganisms [35]. The secretion of cytokines will promote a third stage, which upholds cells
proliferation, angiogenesis, tissue granulation and ultimately promotes the formation of a temporary
extracellular matrix. This mass is then replaced by a mature scar at the remodelling stage of the skin.
This regenerative process is potentially hampered by infection, which can be of fungal or
bacterial origin, with the most prevalent microorganisms being Staphylococcus aureus (gram-positive
bacteria), Pseudomonas aeruginosa [36,37] (gram-negative bacteria) and Candida spp. (fungi) [3].
Infection constitutes a major concern, as the production of a biofilm in the extracellular matrix protects
the microorganisms against conventional antibiotics and is highly associated with hypertrophic
scar [37]. After a burn injury, with the thermal destruction of the skin and the haemostasis phase,
the burn wound surface takes the form of an avascular necrotic tissue with high protein content,
which results in impaired immune cells migration and provides a favourable environment to microbial
invasion and colonization. Gram-positive bacteria of endogenous origin that survive thermal stress,
namely Staphylococci, are the first to colonize the burn wound within the first 48 h, followed by
other pathogens [38]. The bacteria then initiate several mechanisms of virulent factors production,
including host cell adhesion, immune system evasion, nutrient acquisition, which can lead to tissue
destruction and systemic invasion if not rapidly intervened. The adhesion and proliferation will later
promote the aggregate of microorganisms that secrete an extracellular matrix (slime) rich in proteins
and polysaccharides, protecting the complex community from harsh environments in a biofilm.
Antibiotherapy, both topical and systemic, plays an important role in the prevention and
treatment of wound infections. However, systemic antibiotics are highly associated with mechanisms
of resistance, which compromise the treatment process. For local wound treatment, the deeper
extension of the burn and increasing eschar thickness, the less reliable is the administration of
systemic antibiotics to the eschar [39]. Therefore, topical antibiotics emerge as an alternative treatment,
as these contribute to a “high and sustained concentration of the antimicrobial at the site of the
infection” [40]. Despite their potential benefits, the results obtained with topical antibiotherapy are
still “suboptimal” [41], which reinforces the need of innovation in topical antibiotic delivery systems.
3. Innovative Nanoparticles for the Treatment and Repair of Burn Wounds
For several decades, antibiotherapy has been successfully used in promoting human health,
associated however with the increase of bacterial resistance [42]. Local antimicrobial treatment may be a
suitable approach to overcome the risk of bacterial resistance as it reduces drug systemic exposure [43].
A range of new drug delivery systems has been proposed to allow the local administration of
antibiotics [43]. Currently available therapeutic options include biological-based approaches for
burn wound healing (immune-based antimicrobial molecules, reactive oxygen species and nitric
oxide generators, antimicrobial agents and therapeutic microorganisms), antimicrobial light and
ultrasound-based wound therapy (phototherapy and shockwave and ultrasound based-therapy),
stem cell based-burn therapy and nanoparticles for the treatment of burn infections and wound
healing [1]. Other options include surgical approaches, skin grafting and skin substitutes, wound
dressings, negative pressure wound therapy (NPWT), pharmacological approaches, and skin tissue
engineering [1,34,44]. The interaction of nanoparticles with the skin, and therefore their life-time in
the site of action, is governed not only by the degree of injury of the skin but also by the type and
size of nanoparticles. Injured and inflamed skin shows loss of its barrier function and higher risk of
nanoparticles absorption to the systemic circulation and can even be entered by particles larger than
the nanometer scale [45]. The ideal nanocarrier for the topical administration of drugs to skin wounds
should be biodegradable, non-toxic and non-immunogenic, and posess the capacity to release the drug
in a controlled fashion. The therapeutic effects should only be limited to the site of action and no
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systemic absorption should be observed. More important than the half-life of the nanoparticles onto
the site of action (bio-resistant versus biodegradable nanoparticles) is their residence time in the wound
which also depends on the cleaning rituals. The residence time of the nanocarrier onto the skin should
also been increased attributed to the mucoadhesive properties of the nanocarrier’s matrix and small
size. The matrix composition (e.g., natural versus synthetic sources) is instrumental for its metabolic
and biodegradation profiles to limit the risk of adverse side effects. The size and type of nanoparticles
should be selected to minimize the systemic absorption, circumventing the pharmacological activity to
the wound.
3.1. Nanosystems for Antimicrobials Delivery
3.1.1. Nanoemulsions (NE)
NEs constute a heterogeneous system of two immiscible liquids stabilized by a suitable
surfactant [32,46–51]. The droplet diameter is usually between 20 and 400 nm and the limit must be less
than 500 nm [52]. NE are a transparent and isotropic dispersion that can be classified in three categories:
water-in-oil (w/o) dispersions, oil-in-water (o/w) dispersions and bicontinuous/multiple emulsion [52].
NEs have many advantages as they are nontoxic and non-irritant [32,46,53], can be integrated into
various types of pharmaceutical forms (foams, liquids, creams, and sprays) [54], have long-term
physical stability which reduces phenomena like creaming, sedimentation, and coalescence [55], can
be used for parenteral and non-parenteral routes as skin and mucosa [54], allow the solubilization of
hydrophilic and hydrophobic active ingredients [52], and frequently the Brownian motion is enough
to compensate the kinetic instability caused by viscosity or gravity [55]. Some disadvantages may
however be pointed out because the stability of NEs is also dependent on the surface electrical charge,
while the size of of NEs can increase by a phenomenon called Ostwald ripening [54].
Bonferoni et al. [56] loaded α-tocopherol (αTph) in NEs composed of chitosan oleate (CS-OA) for
treatment of skin wounds. Both chitosan and oleic acid are known for their positive effects in wound
healing. The authors reported that CS-OA and αTph NEs promote cell proliferation in keratinocytes
and fibroblast cell cultures. The study suggested that CS-OA and αTph are appropriate for topical
application in wound healing [57].
Song et al. evaluated the antibacterial and anti-biofilm activity of a chlorhexidine acetate NE (CNE)
against skin burn wound methicillin-resistant Staphylococcus aureus (MRSA) infections. The results
showed that in comparison to the aqueous solution of the same drug, CNE had a better and faster
action against MRSA and was more efficient at anti-biofilm activity (inhibiting biofilm formation and
clearing the biofilm). Furthermore, CNE intensely disrupted cell walls and membranes of MRSA [58].
3.1.2. Polymeric Nanoparticles
Polymeric nanoparticles can be produced from natural, semi-synthetic or synthetic polymers to
obtain particles within the range of 10–1000 nm. Depending on the type of polymer, drugs can be
encapsulated (either dissolved or dispersed) within the nanoparticle matrix or attached onto its surface
(chemically bound). The ability of polymeric nanoparticles to permeate skin layers depends on their
chemical composition, the particle size, and the viscosity of the formulation [54]. They have several
advantages such as easy manufacturing, physical and chemical stability [59], diversity of sizes and
shapes [60], high drug loading capacity, and the possibility of controlled drug release and targeting [59].
Natural polymers exhibit biocompatibility and biodegradability but have some drawbacks such as
batch variability and the risk of being immunogenic. Synthetic polymers, as they have known chemical
composition, make it easier to predict their properties [61].
Regarding natural polymers, chitosan has been extensively studied in this field. Chitosan is
a polysaccharide formed by a randomly distributed β-(1→4)-linked D-glucosamine and
N-acetyl-D-glucosamine monomers. The chitosan types differ in molecular weight, degree and
pattern of N-acetylation [62]. They are obtained by the process of alkaline deacetylation of chitin [63].
Int. J. Mol. Sci. 2020, 21, 393 6 of 18
Chitin is found in the exoskeleton of crustaceans, insects and fungal cell walls [64]. The chitosan pKa
is approximately 6.5, being soluble in acid medium and insoluble in alkaline and neutral media [63].
Chitosan has been investigated for use in several areas such as food, cosmetic, pharmaceutical and
agrochemical industries [34,44,62,65–67]. Chitosan is non-toxic, biocompatible, biodegradable [63],
has antimicrobial activity, and low immunogenicity while properties like mucoadhesion, controlled
drug delivery, and in situ gelation improve permeation [68]. The antimicrobial activity of chitosan is
attributed to several mechanisms, namely, (i) interference of the chitosan molecules (which have a
positive charge) in the bacterial surface (which has a negative charge) by modifying the permeability
of the cell membrane, (ii) inhibition of the mRNA and protein synthesis by hydrolysis products,
(iii) restriction of cell growth, by forming chelates with nutrients and essential metals, and (iv)
inhibition of oxygen (essential to the growth of aerobic bacteria) and nutrients by a polymer membrane
which surrounds the surface of the cell [69].
Chitosan has been associated with the ability to improve wound healing. because it enhances the
activity of fibroblasts, macrophages and polymorphonuclear leukocytes [70].
Nguyen et al. incorporated fibroblast growth factor 2 (FGF-2), a protein that participates in
wound healing but highly unstable in vivo, in carboxylmethyl chitosan (CMCS) nanoparticles [71].
Nanoparticles composed of CMCS:CaCl2 (ratio of 1:0.8) with 95% of encapsulation efficiency for FGF-2
were produced using CaCl2 as crosslinking agent. Particles were incubated in pH 7.4 and 5.8 media for
48 h, during which 36.36% and 58.47% release of FGF-2, respectively, were recorded. The obtained
results reveal that in vitro degradation of FGF-2 by trypsin could be avoided by the loading of the
protein into the CMCS nanoparticles, and that the activity of FGF-2 was not compromised by the
encapsulation and release process.
Ding et al. described the cross-linking of chitosan with genipin following the adding of partially
oxidized Bletilla striata polysaccharide to prepare a new biomaterial for the treatment of wounds
(CSGB) [72]. The developed material exhibited lower gelation time, increased water retention and
increased proliferation of L929 cells when compared to chitosan cross-linked only with genipin.
The CSGB has however practically lost the antibacterial action because the amino groups of chitosan
were partially inhibited. To overcome this problem, the authors prepared a bilayer composite of
chitosan-silver nanoparticles (CS-AgG) on CSGB. This study allowed to conclude that either CSGB or
bilayer wound dressing accelerated the wound healing in mice. The bilayer also showed enhanced
epidermization with a decrease in inflammatory cells.
El-Feky et al. loaded silver sulfadiazine (SSD) in chitosan nanoparticles as a dressing for burn
wound treatment [73]. The particles showed controlled release of SSD, which inhibited the proliferation
of Gram-negative and Gram-positive bacteria and Candida albicans in an infected wound.
Blaževic´ et al. developed melatonin-loaded lecithin/chitosan nanoparticles and and tested their
effect on the wound epithelialisation in vitro [74]. Four different types of chitosan were tested for their
biocompatibility and in vitro release of melatonin. The potential to promote wound epithelialization
was evaluated by an in vitro scratch assay using a human keratinocyte (HaCaT) monolayer. A 5 µg/mL
chitosan concentration of nanoparticles was tested on model wounds. The combination of chitosan
and melatonin promoted wound epithelialization, while the effect on the proliferation and migration
of keratinocytes was independent of the type of chitosan used for the production of nanoparticles.
3.1.3. Metal Nanoparticles
Metal nanoparticles have been used for different purposes such as medical imaging, diagnostics,
drug delivery, antimicrobial coatings and environmental sensors [75,76]. Their use in the treatment of
infections is of great relevance because of the recognised antimicrobial properties associated with a high
surface/volume ratio [77]. Silver nanoparticles have been extensively used for this purpose [76]. Silver is
a shiny, greyish metal that has been used for medicinal purposes for many years. Formulations with
AgNPs are more effective than when silver is used in its macroscopic counter-parts. Silver nanoparticles
can be produced by physical methods (e.g., evaporation-condensation and laser ablation), chemical
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methods (e.g., chemical reduction with a reducing agent) or biological methods (e.g., synthesis by
microorganisms) [78]. The antimicrobial properties of silver are due to the ability to disturb the plasma
membrane, which alters the permeability, resulting in lysis of the microorganism. AgNPs may also
bind to the DNA, preventing its replication, or bind to the ribosomes preventing protein synthesis [75].
Mehrabani et al. prepared scaffolds from silk fibroin/chitin/silver nanoparticles by freeze-drying [79].
The antimicrobial activity of the obtained scaffolds was evaluated against Escherichia coli, Staphylococcus
aureus, and Candida albicans, and these were shown to be biocompatible (cytocompatible) and
biodegradable, with high antimicrobial activity, blood clotting, and water-uptake capability.
Tabaii and Emtiazi produced transparent bacterial cellulose membranes impregnated with
antimicrobial AgNPs [80]. The AgNPs showed a diameter between 20–60 nm, while the AgNPs/BC
membranes exhibited long-term stability with a high antimicrobial activity against Escherichia coli and
Staphylococcus aureus.
3.1.4. Nanogels
Nanogels consist of hydrogels composed of particles within the range of nanometers [81].
Hydrogels are three-dimensional cross-linked polymeric networks and have the capacity to uptake
high amount of water or biological fluid [82]. Their loading with drugs is spontaneous and the
production does not require mechanical energy or organic solvents [83]. Nanogels are biocompatible
and prevent the enzymatic degradation of the drug [81], but those produced from particles with smaller
size than the pore meshes in nanogels have the risk of leakage from nanogels network [81].
El-Feky et al. produced several silver sulfadiazine loaded nanogels based on chitosan and
alginate [84]. The in vitro release studies in phosphate buffer (pH 7.4) showed a burst release of the
drug followed by a prolonged release over a period of 3 h. In comparison to marketed products of the
same drug, the developed nanogels had greater therapeutic efficacy in vivo in a female rat model of
burn wound.
3.2. Wound Dressings
Wounds can be classified as acute or chronic, and can be divided into subclasses, such as
pressure ulcers, venous leg ulcers, diabetic foot ulcers, traumatic wounds and surgical wounds [34,44].
Wound dressings allow to cover the wound, accelerating the healing and protecting it from external
aggressions, such as damages, desiccation and microorganisms [85]. An ideal dressing should remove
the excess of the exudate, it should moisturize and protect the skin, allow a clean, warm and moist
environment, together with an adequate gaseous exchange, easy to use and be cost-effective. In addition,
dressings should not release fibers or particles from their composition, or cause pain upon application
or removal [34,44,86].
Wound dressings may present different physical forms, such as sponges, films, membranes,
hydrogels or hydrocolloids [87], and can be divided into two categories: (i) traditional wound dressing,
or (ii) modern wound dressing. Traditional wound dressings are used as primary dressings on clean
and dry wounds with little exudation or as secondary dressing. Some examples are gauzes, bandages
and plasters. Most of these products have to be changed regularly and adhere easily to the wound
causing difficulties at the time of removal. For these reasons, modern dressings are more used because
they maintain a humid environment and accelerate cicatrisation. There is a great variety of modern
wound dressings, most of them based on synthetic polymers [88].
It is usual to classify wound dressings into four classes: biological dressings, conventional
dressings, biosynthetic dressings, and antimicrobial dressings [85]. The purpose of using antimicrobial
dressings is to prevent bacterial infections in burn wounds that are more susceptible to invasion by
microorganisms. There are several antimicrobial agents that can be used in wound dressings [85].
To choose the antimicrobial agent, one must consider its specificity and efficacy, the potential to induce
resistance and its safety in terms of cytotoxicity and allergenicity [89]. Antibiotics, nanoparticles
and natural products (e.g., chitosan) are examples of antimicrobial agents [87]. It is common to find
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antimicrobial dressings containing silver (ionic silver-impregnated dressings and silver sulfadiazine),
iodine (povidone iodine and cadexomer iodine) or natural products (such as honey) that are debriding
agent and can mask odours [85,89]. The use of silver compounds in the treatment of burns has a
fundamental role in decreasing the number of cases of sepsis and death [85]. The period of use of
antimicrobial products should be as short as possible, preferably less than two weeks [89].
Biswas et al. produced porous chitosan/PVA (CS) scaffolds (CS-Se and CS Ag) by an in situ
deposition method to be loaded either with silver (Ag) or selenium (Se) to be used in wound
dressings [90]. The activity of these two types of scaffolds has been evaluated against gram-positive
bacterium (Staphylococcus aureus), gram-negative bacterium (Escherichia coli), and multi-resistant
(methicillin-resistant S. aureus, MRSA) bacteria. The Ag-loaded scaffolds showed a strong bactericidal
activity against the studied species, but caused cytotoxicity in fibroblasts. The Se-loaded scaffolds were
shown to be membranolytic against the studied strains and were non-toxic towards fibroblast
Kaygusuz et al. compared the antibacterial properties of cerium (III) crosslinked alginate films
(Ce films) and cerium (III)-chitosan crosslinked alginate films (Ce-Chi films), with conventional calcium
alginate films, against Escherichia coli (Gram-negative bacteria) and Staphylococcus aureus (Gram-positive
bacteria) [91]. The results showed that Ce and Ce-Chi films had higher antibacterial activity than films
with calcium. Ce and Ce-Chi films also showed improved physical properties and flexibility. The study
suggested that Ce-Chi films can be used in antibacterial wound dressings.
3.3. Tissue Engineering
Tissue engineering and regenerative medicine (TERM) is an interdisciplinary field that combines
engineering and biology with clinical practice [92]. In acute and chronic thermal injuries, skin tissue
engineering aims to enhance wound healing, trigger skin regeneration and reduce the long term
consequences of scarring with the development of innovative biomaterials, advanced technologies
(such as electrospinning, recombinant proteins, 3D printing) and new methods to incorporate autologous
cells [85]. Scaffolds, cells and growth factors can be combined in the construction of three-dimensional
structures for skin regeneration for the treatment of burn wound. For further illustrations, please refer
to Ho et al. [93].
It has been reported that the use of alpha-gal nanoparticles, composed of glycolipids with alpha-gal
epitopes, phospholipids, and cholesterol, to wounds has induced accelerated healing by harnessing
the natural anti-Gal antibody [94]. The healing time was reduced by 40%–60%, associated to the
increased tropism of macrophages, angiogenesis, as well as epidermis and dermis growth. It has also
been reported that such an approach could significantly reduce the risk of fibrosis and formation
of scars. Biomaterials used in tissue engineering can be of natural or synthetic polymeric nature.
Natural biomaterials include commercial products based on collagen, hyaluronic acid, elastin, chitin
and fibrin [85,95], which are favourable to skin tissue regeneration due to their mechanical similarity,
biocompatibility and biodegradability properties. Synthetic polymers include polylactic acid and
polyglycolic acid, which can be used as cell growth support in scaffolds [95].
Steffens et al. developed an acellular matrix of poly-d,l-lactic acid (PDLLA) scaffolds produced by
the electrospinning technique, linked to laminin-332 protein (isoformα3β3γ2) [95]. The electrospinning
technique, by submitting a polymeric solution to an electric field, allowed the formation of a solid
fibrous structure that would mimic the extracellular matrix arrangement and support cell growth.
The inclusion of laminin, as a cell adhesion natural protein, was based on its importance in keratinocyte
migration. The skin substitute was posteriorly completed with the inclusion of a cellular component
constituted by mesenchymal stem cells and keratinocytes, directed to the dermal and epidermal skin
regeneration, respectively.
Several other innovative therapies for burn wound treatment have also been proposed, among
which is the use of recombinant proteins [96], such as elastin-like polypeptides [97]. Elastin is a
biocompatible natural human skin component with structural functions [97]. Based on hypertrophic
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scarring related to the augmented expression of collagen and low elastin fiber production, tropoelastin
delivery aims to the improvement of skin flexibility in burn wound healing [98].
Xie et al. studied the impact subcutaneous injections of recombinant human tropoelastin in skin
flexibility in partial thickness thermal wounds [98]. As a soluble precursor of elastin, tropoelastin
was used to enable elastin fiber production in burn and surgical scars. The treatment evidenced the
production of new elastin fibers in site, although no improvement in skin flexibility was observed [98].
Thermal injuries may represent extensive skin damage. Full-thickness burns are a major concern,
as the full integrity of the skin has been completely compromised, to the point in which it has no
capacity to repair autologously [99]. Situations like full-thickness burns (3rd and 4th degrees, Figure 1)
require a skin substitute therapy, such as three-dimensional biocompatible structures to provide skin
regeneration in burn wound healing [99].
Law et al. characterized hyaluronic acid methylcellulose (HAMC) hydrogels for 3D bioprinting [100].
The suitability of HAMC for cell-encapsulated three-dimensional bioprinting applications, adequate for
scaffold structures and cell delivery, with mesenchymal stem cell viability for one week (minimum) in
bioprinted structures has been confirmed [100].
Combining tissue engineering, regenerative medicine and 3D printing (by placing cells and
extracellular matrix in tissue native microenvironments) with big data analysis is offering new
perspectives in the treatment of burn wound patients [101].
Gholipourmalekabadi et al. developed a 3D bi-layer scaffold of biological decellularized
human amniotic membrane (AM) with viscoelastic electrospun nanofibrous silk fibroin (ESF) [102].
Adipose tissue-derived mesenchymal stem cells (AT-MSCs), cultured for seven days on the AM-ESF
scaffold, demonstrated the expression of vascular endothelial growth factor (VEGF) and basic fibroblast
growth factor (bFGF), which suggests potential suitability for AM/ESF scaffold with autologous
AT-MSCs [102].
Kuna et al. produced a novel composite gel from human peripheral blood mononuclear cells
(hPBMCs) and decellularized gal-gal-knockout porcine skin for skin wound healing [103]. To obtain a
pig skin gel (PSG), the prepared decellularized skin extracellular matrix (ECM) powder was mixed
with culture medium containing hyaluronic acid. Nude mice were used to evaluate the effect of the
composite in regeneration of wounds, showing a significant wound closure within 15 days of treatment
with PSG only or with PSG containing hPBMCs. The addition of hPBMCs to PSG improved the host
blood vessels network and induced the development of human blood vessels.
A bio-ink prepared using skin decellularized ECM has been recently described [104]. The bio-ink
was obtained by combining decellularized ECM (containing collagen, glycosaminoglycans and growth
factors and free from immune-reactive cells) with human dermal fibroblasts. The obtained construct
showed viability over 90%, demonstrating skin regenerative effect of the bio-ink.
The delivery of growth factors to the burn wound was also studied as a tissue engineering
technology, presenting beneficial effects in tissue repair. Liu et al. developed bFGF-loaded alginate
microspheres (Ms) incorporated into carboxymethyl chitosan (CMCS)–poly(vinyl alcohol) (PVA) as
a composite hydrogel, enabling basic fibroblast growth factor delivery without bioactivity loss [99].
The studies comprised a 2-weeks treatment in vivo in rats, in which improved wound recovery rates,
with re-epithelialization and regeneration of the dermis was seen [99]. However, when addressing
burn wound treatment, it is important to take in consideration that compromised skin tissue is greatly
associated to functional limitations and infection susceptibility, which may affect the success of tissue
engineering technologies.
To address these limitations, several studies have been carried out towards the development of
an ideal wound dressing that would combine both skin regeneration and infection control, generally
focused on silver antimicrobial and biosensor activities [105]. Table 2 summarizes some examples.
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Table 2. Summary of the recent studies on nanosystems, wound dressings and tissue engineering for burn wound infection.
Recent Studies on Nanoparticles for Antimicrobials Delivery
System Antimicrobial Compounds Study Description References
Nanoemulsions (NEs)
Chitosan oleate and
α-tocopherol NEs α-tocopherol and chitosan
Encapsulation of α-tocopherol by chitosan oleate. The results indicated that both compounds
promote cell proliferation on keratinocytes and fibroblast cell cultures. [56]
Chlorhexidine acetate NEs
(CNE) Chlorhexidine acetate
Evaluation of the antibacterial and anti-biofilm activity of CNE against methicillin-resistant
Staphylococcus aureus infections. [58]
Polymeric nanoparticles
Carboxylmethylchitosan
nanoparticles (CMCS-NPs) -
Incorporation of fibroblast growth factor 2 in CMCS:CaCl2 NPs. The results show that the
nanoparticles were able to avoid the destruction of FGF-2 by trypsin. [71]
Carbohydrate Polymers Bletillastriata polysaccharideand genipin
Evaluation of the various physico-chemical and biological characteristics of partially
oxidized Bletillastriata polysaccharide to chitosan cross-linked with genipin. [72]
Silver sulfadiazine (SSD) loaded
chitosan nanoparticles (CSNPs) Silver sulfadiazine
Particle optimization and characterization of physical properties, antibacterial efficacy and
fungicidal activity for the dressing with silver sulfadiazine (SSD) loaded chitosan
nanoparticles (CSNPs). Results shown inhibition of the proliferation of Gram negative and
Gram-positive bacteria and Candida albicans.
[73]
Melatonin-loaded
lecithin/chitosan nanoparticles -
Preparation of nanoparticles with four different types of chitosan. Nanoparticles
characterization and biocompatibility and study of the in vitro release of melatonin. [74]
Metallic nanoparticles
Fibroin/chitin/silver
nanoparticles Silver
Preparation of silk fibroin/chitin/silver nanoparticles scaffolds by freeze-drying method,
characterization and antimicrobial activity against Escherichia coli, Staphylococcus aureus,
and Candida albicans.
[79]
Silver nanoparticles Silver
Preparation of antimicrobial silver nanoparticles/bacterial cellulose (AgNPs/BC) membranes
and their characterization, biocompatibility and antimicrobial activity. The results shown
good antimicrobial activity against Escherichia coli and Staphylococcus aureus.
[80]
Nanogels
Silver sulfadiazine nanogel Silver sulfadiazine Optimization and characterization of several silver sulfadiazine loaded nanogel formulations. [84]
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Table 2. Cont.
Recent studies on wound dressings
System Antimicrobial Compounds Study Description References
Silver-loaded scaffolds and
Selenium-loaded scaffolds Silver and selenium
Incorporation of silver and selenium separately into porous chitosan/PVA scaffolds by in situ deposition
method. Characterization of scaffolds with Se or Ag nanostructures respectively, and antimicrobial
activity against Staphylococcus aureus, Escherichia coli, and Methicillin-Resistant S. Aureus.
[90]
Cerium(III)crosslinked alginate films and
cerium(III)-chitosan crosslinked alginate films Cerium
Preparation of crosslinked alginate films and cerium (III)-chitosan crosslinked alginate films,
characterization and comparation to physical and antibacterial properties of conventional calcium
alginate films. Test of antimicrobial activity in Escherichia coli and Staphylococcus aureus.
[91]
Tissue engineering
System Antimicrobial Compounds Study Description References
Acellular matrix of poly-d,l-lactic
acid scaffolds -
Development of an acellular matrix of poly-d,l-lactic acid (PDLLA) scaffolds produced by the
electrospinning technique, linked to laminin-332 protein (isoform α3β3γ2), completed with the
inclusion of a cellular component constituted by mesenchymal stem cells and keratinocytes.
[95]
Subcutaneous injections of recombinant
human tropoelastin -
The impact of subcutaneous injections of recombinant human tropoelastin in skin flexibility, in partial
thickness thermal wounds. [98]
Methylcellulose Hydrogels for
cell-encapsulated 3D bioprinting -
Characterization of hyaluronic acid methylcellulose (HAMC) hydrogels for 3D bioprinting, adequate for
scaffold structures and cell delivery. [100]
3D bi-layer scaffold of biological decellularized
human amniotic membrane (AM) with
viscoelastic electrospun nanofibrous silk
fibroin (ESF) and incorporated adipose
tissue-derived mesenchymal stem cells.
-
Development of a 3D bi-layer scaffold of biological decellularized human amniotic membrane (AM)
with viscoelastic electrospun nanofibrous silk fibroin (ESF). Adipose tissue-derived mesenchymal stem
cells (AT-MSCs) cultured for seven days on the AM-ESF scaffold, demonstrated the expression of
vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF).
[102]
bFGF-loaded alginate microspheres (Ms)
incorporated into a carboxymethyl
chitosan-poly(vinyl alcohol) hydrogel.
- Development of bFGF-loaded alginate microspheres (Ms) incorporated into carboxymethyl chitosan(CMCS)–poly(vinyl alcohol) (PVA) as a composite hydrogel. [99]
Hydroxyethyl cellulose-silver nanoparticle
(HEC-AgNP) lyophilized scaffold Silver nanoparticles
Development of a hydroxyethyl cellulose-silver nanoparticle (HEC-AgNP) lyophilized scaffold, using
freeze-dry methodology. [106]
Polydopamine and collagens type I, V, X
eggshell membrane loaded with
silver nanoparticles
Silver nanoparticles
Study of the incorporation of silver nanoparticles on the surface of a natural biomaterial of collagens
type I, V and X (eggshell membrane) using polydopamine mediated adhesion and reduction properties,
which exhibited benefits for tissue regeneration, biocompatibility and low toxicity.
[107]
Crosslinked electrospun gelatin fibers loaded
with gentamicin sulfate and ciprofloxacin
Gentamicin sulfate and
ciprofloxacin
Development of crosslinked electrospun gelatin fibers loaded with gentamicin sulfate and hydrophobic
ciprofloxacin release for deep infected burns, against Pseudomonas aeruginosa and Staphylococcus
epidermidis infections.
[107]
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Zulkifli et al. developed a hydroxyethyl cellulose-silver nanoparticle (HEC-AgNP) lyophilized
scaffold [106]. In this study, hydroxyethyl cellulose serves as a polymer matrix and a reducing agent of
silver ions to a zero-valent form and nanoparticle formation using freeze-dry methodology. When in
contact with moisture or wound fluid, silver ions are released, inhibiting bacterial growth, without
toxicity effects on human fibroblast cell growth [106].
Advanced studies of AgNP delivery systems allowed not only the delivery of nanoparticles, but
also the development and optimization of control release of the nanoparticles from the scaffold to the
burn wound. Liu et al. studied the incorporation of silver nanoparticles on the surface of a natural
biomaterial of collagens type I, V, and X (eggshell membrane) using polydopamine mediated adhesion
and reduction properties, which exhibited benefits for tissue regeneration, biocompatibility, and low
toxicity [105,107].
Despite the aforementioned technological progress and silver broad antimicrobial activity, there
are some limitations associated with silver products, such as cytotoxicity to host cells (fibroblasts and
keratinocytes) and emergence of bacterial resistant strains (e.g., Escherichia coli) [108]. Topical antibiotic
delivery may comprise an alternative approach for the treatment of burn wound infection.
Chen et al. developed electrospun gelatin fibres with gentamicin sulfate and hydrophobic
ciprofloxacin release for deep infected burns, with evidenced effectiveness against Pseudomonas
aeruginosa and Staphylococcus epidermidis infections [107]. The electrospinning technique allowed the
formation of a fibrous structure that would mimic the extracellular matrix, composed of a cross-linked
fibre of denatured collagen derivative (gelatin) and alginate dialdehyde. This product was loaded with
the antibiotics, allowing the prompt gentamicin sulfate delivery and ciprofloxacin sustained release, for
initial and maintenance infection control, respectively. This combined system, demonstrated successful
antibiotic release and accelerated dermal regeneration in burn wound infection [107].
4. Conclusions
In the past few years, several efforts have been made to improve the way wound infections are
treated. Technological developments in the field of nanomedicines have been instrumental in finding
new alternatives to overcome antimicrobial resistance against antibiotics Several types of nanoparticles
have been proposed, e.g., nanoemulsions, polymeric nanoparticles, metal nanoparticles, nanogels, with
the aim to enhance the antimicrobial activity of compounds. The choice of nanoparticle is governed by
the type of drug and by the extend of injured skin. Wound dressings made from, e.g., sponges, films,
membranes, hydrogels or hydrocolloids, have also been proposed to offer protection against invasive
microorganisms and accelerate the healing process, while regenerative medicine and tissue engineering
make use of scaffolds, cells and growth factors for the construction of three-dimensional structures
for skin regeneration. Future perspectives in the treatment of wound burns encompass the use of
mesenchyme stem cells and progenitor cells, combined with nanomedicines, as these cells are known
to be involved in skin regeneration. The delivery of cytokines, growth factors, and inflammatory
mediators may further improve the healing process contributing for a synergistic effect in the treatment
of wound burns.
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